Navigation Links
Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
Date:3/23/2009

- Hank Nordhoff, CEO Since 1994, to Serve as Non-Executive Chairman of the Board -

SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that its board of directors has elected Carl W. Hull the Company's new chief executive officer (CEO), effective May 18, 2009. He also is expected to join the Company's board of directors at that time.

Mr. Hull, currently Gen-Probe's president and chief operating officer, will become president and CEO following the retirement of Henry L. Nordhoff as the Company's CEO on May 17, 2009. Mr. Nordhoff, who has served as Gen-Probe's chief executive officer since 1994, will become non-executive chairman upon his re-election to the board by stockholders at the Company's 2009 annual meeting.

"I'm delighted to announce the board's unanimous election of Carl as Gen-Probe's next CEO," Nordhoff said. "He brings unparalleled experience in our field and a deep understanding of molecular diagnostics. His keen intellect and unflagging energy will prove invaluable as he takes the helm of the Company."

"In nearly 15 years as CEO of Gen-Probe, Hank has presided over tremendous business growth, product innovation and shareholder value creation," said Armin Kessler, Gen-Probe's lead independent director and former chief operating officer of Hoffman-La Roche. "The Company has grown from a subsidiary of Chugai, with $61 million in annual revenues, to a public company with a market capitalization exceeding $2 billion and revenues of $473 million last year. Gen-Probe's customers, employees and shareholders owe him a debt of gratitude, and the board is fortunate to be able to continue benefiting from his guidance and leadership."

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release relating to expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements regarding future growth, the composition of the board of directors, and the plans and objectives of management are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks include, but are not limited to, the risk that we cannot retain key executives. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

    Contact:

    Michael Watts
    Vice president, investor relations and corporate communications
    858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tepnel Shareholders Approve Acquisition by Gen-Probe
2. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
3. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
4. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
5. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
6. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
9. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology: